Seguros Bolívar
Biopharma Applies New Service and Support Models amid COVID-19
Article

Biopharma Applies New Service and Support Models amid COVID-19

Friedemann Wolf, Stephen Waddell, Mauro Castilhos and Ulrik Schulze
Boston Consulting Group, 2020
Read the article

Read or listen offline

Amazon Kindle
  • 0.5×
  • 0.75×
  • 1×
  • 1.25×
  • 1.5×
  • 1.75×
1×

Editorial Rating

8

Qualities

  • Overview
  • Hot Topic

Recommendation

Patients are avoiding in-person appointments, and fewer hospitals are accepting face-to-face visits with biopharma staff. What does an industry that’s driven by in-person interactions do in the COVID-19 era? According to the Boston Consulting Group, what businesses have always done: adapt. Virtual diagnostics or telemedicine for health care providers, hyper-segmentation and data-driven processes for biopharma companies – these are the development that will see you through the pandemic and ensure your post-COVID success.

Summary

The biopharma industry usually revolves around in-person meetings. COVID-19 has changed that.

Biopharma staff are having fewer face-to-face interactions with doctors, and fears about COVID-19 are keeping patients from in-person office visits. Overall, the pandemic has led to a reduction in prescriptions and trips to the pharmacy. 

Biopharma companies are finding new ways to add value during the pandemic, however. They’ve created virtual infrastructure to maintain communication with health care providers, and are adapting to treatment and supply limitations. Companies are also deploying their staff to assist in Coronavirus labs and testing facilities. 

Industry leaders are tackling the pandemic in three stages: the near-term, the medium term and the longer term.

In the near...

About the Authors

Friedemann Wolf, Stephen Waddell, Susan Schriver and Ulrik Schulze are managing directors and partners in the Boston Consulting Group's Hamburg, Chicago, New York and Zurich offices.

Comment on this summary or Iniciar a Discussão